# SELLAS Life Sciences Stock Drops 14% Weekly Ahead of ASH Conference

- URL: https://stocks.freetheai.org/news/sellas-life-sciences-stock-drops-14-weekly-ahead-of-ash-conference-8f5272
- Published: 2026-10-19T03:44:49Z
- Category: company_news; sentiment: bearish; impact: medium
- Symbols: [NASDAQ:SLS](https://stocks.freetheai.org/symbols/NASDAQ-SLS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

SELLAS Life Sciences Group, Inc. (SLS) closed nearly 12% lower at $9.98 on Friday, extending a three-session decline and ending the week down 14%. The slide marked the worst weekly performance in over a month for the biotechnology company, though shares remain up 165% year-to-date.

Investor attention has shifted toward the upcoming American Society of Hematology annual meeting in New Orleans, where Sellas has secured exhibit space. Market participants are anticipating potential updates on Galinpepimut-S, the company's immunotherapy candidate in Phase 3 testing for acute myeloid leukemia. The Regal trial requires 80 events to trigger a final analysis, with 78 events recorded at the last update. Abstract releases for the conference are governed by embargo policies set for Nov. 4 and Dec. 7.

Looking ahead, Sellas also plans to disclose fourth-quarter topline results from an 80-patient Phase 2 trial of SLS009 in acute myeloid leukemia. Preclinical laboratory studies have also demonstrated activity for SLS009 when combined with Daraxonrasib in resistant pancreatic cancer models.

## Key points

- SELLAS Life Sciences Group, Inc. (SLS) stock fell 11.99% on Friday to $9.98, logging a 14% weekly loss.
- Investors are watching the upcoming ASH conference in New Orleans for updates on the Phase 3 Regal study.
- The Phase 3 Regal trial requires 80 events to trigger its final analysis, with 78 previously reported.
- Sellas expects fourth-quarter Phase 2 topline results for SLS009 in acute myeloid leukemia.

## Questions and answers

### Why did Sellas Life Sciences stock drop on Friday?

Sellas Life Sciences stock fell 11.99% on Friday to $9.98, completing a three-session losing streak and a 14% weekly decline, marking its worst week in over a month.

### What is the main clinical trial milestone Sellas investors are watching?

Investors are monitoring the Phase 3 Regal trial evaluating Galinpepimut-S in acute myeloid leukemia, which requires 80 death events to trigger its final analysis after reaching 78 at its last disclosure.

### When will trial results be unembargoed for the ASH conference?

Abstract data for the American Society of Hematology conference remains under embargo until Nov. 4 for regular abstracts and Dec. 7 for late-breaking submissions.